KPTI

+ Watchlist + Portfolio

Karyopharm Therapeutics Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.87
52-Week Range: $0.75 – $10.99
Market Cap: $18.20M
P/E (TTM): —
EPS (TTM): -14.33
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -47.61%
Gross Margin: 99.06%
Operating Margin: -67.38%
Profit Margin: -153.28%
Current Ratio: 0.79
Debt/Equity: —
Total Debt: $328.53M
Free Cash Flow: $-29.67M
Revenue Growth: -11.90%
Earnings Growth: —
Enterprise Value: $281.62M

KPTI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$157.07M	$146.03M	$145.24M	$146.07M
Cost of Revenue	$5.21M	$4.94M	$6.01M	$5.95M
Gross Profit	$151.86M	$141.09M	$139.23M	$140.12M
Research & Development	$148.66M	$138.75M	$143.23M	$125.62M
Selling, General & Admin	$145.40M	$131.88M	$115.44M	$105.21M
Operating Expenses	$294.06M	$270.63M	$258.67M	$230.82M
Operating Income	-$142.20M	-$129.54M	-$119.44M	-$90.71M
EBITDA	-$139.31M	-$118.42M	-$38.60M	-$149.85M
Pretax Income	-$164.92M	-$142.78M	-$76.36M	-$196.00M
Income Tax	$369.00K	$323.00K	$57.00K	$43.00K
Net Income	-$165.29M	-$143.10M	-$76.42M	-$196.04M
Diluted EPS	-30.30	-18.79	-13.95	-17.93
Diluted Shares	5.46M	7.62M	8.45M	10.94M

KPTI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$135.19M	$52.23M	$62.48M	$60.54M
Receivables	$47.09M	$26.96M	$30.77M	$26.18M
Inventory	$4.22M	$3.04M	$4.74M	$4.04M
Current Assets	$350.16M	$233.92M	$156.46M	$103.15M
Total Assets	$358.17M	$240.44M	$164.42M	$108.42M
Current Liabilities	$65.91M	$69.48M	$92.26M	$92.06M
Long-Term Debt	$170.10M	$170.92M	$162.95M	$205.88M
Total Debt	$179.07M	$177.02M	$194.52M	$233.61M
Total Liabilities	$374.83M	$376.64M	$350.44M	$401.34M
Retained Earnings	-$1.34B	-$1.49B	-$1.56B	-$1.76B
Shareholders' Equity	-$16.66M	-$136.21M	-$186.02M	-$292.93M
Working Capital	$284.25M	$164.44M	$64.20M	$11.09M
Net Debt	$34.92M	$118.69M	$124.90M	$166.35M

KPTI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$149.55M	-$92.72M	-$127.49M	-$75.37M
Capital Expenditure	-$118.00K	—	-$142.00K	—
Free Cash Flow	-$149.67M	-$92.72M	-$127.63M	-$75.37M
Depreciation & Amortisation	$621.00K	$530.00K	$340.00K	$296.00K
Stock-Based Compensation	$35.40M	$21.71M	$18.43M	$14.05M
Investing Cash Flow	-$104.26M	$7.94M	$95.47M	$43.38M
Financing Cash Flow	$193.74M	$1.12M	$41.65M	$30.05M
Net Change in Cash	-$60.07M	-$83.66M	$9.63M	-$1.94M

KPTI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$30.02M	$37.93M	$44.04M	$34.08M	$35.07M	$33.43M
Cost of Revenue	$1.30M	$1.05M	$2.11M	$1.48M	$1.34M	$1.08M
Gross Profit	$28.71M	$36.88M	$41.93M	$32.59M	$33.72M	$32.35M
Research & Development	$34.62M	$32.79M	$30.54M	$27.67M	$33.80M	$28.96M
Selling, General & Admin	$27.35M	$28.48M	$26.61M	$22.77M	$26.68M	$25.92M
Operating Expenses	$61.97M	$61.27M	$57.15M	$50.44M	$60.48M	$54.87M
Operating Income	-$33.26M	-$24.39M	-$15.22M	-$17.84M	-$26.76M	-$22.53M
EBITDA	-$12.35M	-$25.91M	-$21.96M	-$89.63M	-$9.83M	-$53.88M
Pretax Income	-$23.43M	-$37.21M	-$33.09M	-$102.27M	-$22.39M	-$67.02M
Income Tax	$36.00K	$40.00K	$34.00K	-$67.00K	$1.00K	$0.00
Net Income	-$23.46M	-$37.25M	-$33.13M	-$102.20M	-$22.39M	-$67.02M
Diluted EPS	-2.77	-4.32	-3.82	-5.71	-1.24	-2.32
Diluted Shares	8.47M	8.62M	8.67M	17.90M	24.71M	28.94M

KPTI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$38.78M	$38.73M	$37.67M	$60.54M	$90.85M	$54.98M
Receivables	$35.24M	$32.93M	$31.88M	$26.18M	$23.36M	$29.87M
Inventory	$4.77M	$4.99M	$3.97M	$4.04M	$3.60M	$3.99M
Current Assets	$120.24M	$97.87M	$89.75M	$103.15M	$126.33M	$106.38M
Total Assets	$127.71M	$104.88M	$96.23M	$108.42M	$131.42M	$111.32M
Current Liabilities	$90.37M	$99.22M	$87.16M	$92.06M	$117.30M	$134.23M
Long-Term Debt	$154.83M	$152.25M	$176.74M	$205.88M	$192.16M	$209.63M
Total Debt	$186.70M	$190.62M	$196.42M	$233.61M	$230.87M	$256.19M
Total Liabilities	$333.60M	$343.81M	$365.49M	$401.34M	$397.06M	$441.49M
Retained Earnings	-$1.59B	-$1.62B	-$1.66B	-$1.76B	-$1.78B	-$1.85B
Shareholders' Equity	-$205.88M	-$238.93M	-$269.26M	-$292.93M	-$265.65M	-$330.17M
Working Capital	$29.87M	-$1.35M	$2.59M	$11.09M	$9.03M	-$27.86M
Net Debt	$140.51M	$144.26M	$151.82M	$166.35M	$133.54M	$194.96M

KPTI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$38.98M	-$18.70M	-$5.86M	-$11.83M	-$22.73M	-$24.93M
Free Cash Flow	-$38.98M	-$18.70M	-$5.86M	-$11.83M	-$22.73M	-$24.93M
Depreciation & Amortisation	$78.00K	$78.00K	$121.00K	$19.00K	$12.00K	-$3.00K
Stock-Based Compensation	$3.56M	$3.78M	$2.80M	$3.90M	$3.01M	$1.93M
Investing Cash Flow	$15.29M	$18.29M	$4.80M	$5.00M	$3.20M	-$10.04M
Financing Cash Flow	$0.00	$356.00K	$0.00	$29.69M	$49.80M	-$898.00K
Net Change in Cash	-$23.70M	-$56.00K	-$1.05M	$22.86M	$30.27M	-$35.87M

Market Snapshot

About

Karyopharm Therapeutics is an oncology-focused pharmaceutical company developing novel drugs using Selective Inhibitor of Nuclear Export (SINE) technology. The company's lead product, selinexor, is approved for multiple cancer indications including multiple myeloma and diffuse large B-cell lymphoma. Karyopharm is advancing additional SINE compounds through clinical development for various hematologic and solid tumor malignancies.